Zip, I agree. Amarin/Fish & Richardson brought this suit against Health Net for a reason. The settlement must provide a value for Amarin beyond this single insurance provider. If not there would be no reason for Amarin to accept it. This is the first time an insurance company has been sued for inducing infringment. Both the magistrate and the judge felt that the case had merit. It's possible that the resolution of this case may have exposed the weak link in the conspiracy, between generic manufacturers and insurance companies. The Hatch Waxman act has been used to end run patent law for far to long. I am not a lawyer, but I can understand the logic presented in the suite. If Preferential payment for the generic does in fact represent an overt act, the "skinny label" provision may be about to end. Perhaps not end , but be used properly. Due to our success, I would expect to see more suits targeting insurers for inducement.
Not necessarily filed by Amarin.
Sleven,
News 
Market Data 
Discover 
